GlassScriptPhysician profile
Mimi Hill
NPI 1699365106
$5,035.10
in general payments reported to CMS, 2019-2025
19 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $931 · 2023: $1,347 · 2024: $1,485 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.06 |
| Education | $166.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.59 | 2021-2025 | |
| Genzyme Corporation | $678.64 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $447.57 | 2022-2025 | |
| Janssen Biotech, INC. | $364.79 | 2021-2024 | Tremfya |
| Lilly USA, LLC | $333.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Revance Therapeutics, INC. | $332.71 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $313.77 | 2023-2024 | Sotyktu |
| Pfizer INC. | $281.89 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $200.65 | 2021-2025 | Winlevi |
| Galderma Laboratories, L.P. | $181.07 | 2024 | Dysport |
| Mayne Pharma Commercial LLC | $151.33 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $86.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $60.87 | 2022-2023 | Libtayo |
| Dermavant Sciences, INC. | $56.34 | 2023-2024 | Vtama |
| Convatec INC. | $39.69 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $28.07 | 2025 | Dexcom G6 Transmitter |
| Incyte Corporation | $24.77 | 2025 | Opzelura |
| Ucb, INC. | $16.83 | 2025 | Bimzelx |
| Organon LLC | $16.22 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.